Abattis Announces An Independent Valuation On Green Nature Health Care Products

Biotech Investing

Abattis Bioceuticals (OTCQB:ATTBF,CSE:ATT) provided an update to its shareholders. As quoted in the press release: Abattis Bioceuticals Corp. has begun an independent valuation on Green Nature Health Care Products Inc., after the company posted strong performance within their existing and upcoming product catalogue in both Q3 and Q4 of 2016. Green Nature, with which Abattis …

Abattis Bioceuticals (OTCQB:ATTBF,CSE:ATT) provided an update to its shareholders.
As quoted in the press release:

Abattis Bioceuticals Corp. has begun an independent valuation on Green Nature Health Care Products Inc., after the company posted strong performance within their existing and upcoming product catalogue in both Q3 and Q4 of 2016. Green Nature, with which Abattis entered into an international licensing and co-branding agreement back in November of 2016, continues to import it’s branded dried-fruit products to some 200 food based supply chains in China, including Shanghai Duty Free (five stores), Yangzhou Pharmacy (20 stores), and Wal-Mart (388 stores). Green Nature’s products are also found in Canada at TNT Markets and ~50 healthcare product stores.
Green Nature recently received a purchase order from a large Japanese supplier (250 national stores) for monthly container shipments of Green Nature’s signature dried fruit products. Green Nature has also started final packaging on several new product lines, including Hemp and Granola products, which the company plans to reveal through its busy tradeshow and sales schedule in 2017. As a result of these developments, Abattis has begun an independent valuation on Green Nature’s business in order to determine its suitability as a strategic acquisition target. The initial agreement between Green Nature and Abattis gives Abattis the right to acquire Green Nature, by issuing common stock, if the opportunity should be deemed as accretive to Abattis by the board.

Click here for the full press release.

The Conversation (0)
×